Ex vivo engineering of hematopoietic stem cells using RNA-LNPs for cell and gene therapies

Delivering nucleic acids using lipid nanoparticles (LNP) to target cells has tremendous potential to enable new cell and gene therapies. In this webinar, we'll share insights on an innovative genomic medicines toolkit, focusing on technologies that streamline the development of RNA-LNP medicines.

We're excited to introduce you to off-the-shelf reagents designed specifically for producing RNA-LNPs optimized for hematopoietic stem cells (HSC), alongside the NanoAssemblr™ manufacturing platform equipped with NxGen™ technology. This platform can enable rapid development and scale-up production of RNA-LNPs. Through this presentation, we will walk you through data for ex vivo hematopoietic stem cell therapies showcasing how LNPs serve as a vehicle for RNA delivery for the transient expression of therapeutic genes and gene-editing nucleases.

Join us in this webinar to learn more about:

• How RNA-LNPs are being used to develop the next-generation of HSC therapies
• How to perform highly efficient gene editing in CD34+ HSCs
• Seamless integration of LNPs in CD34+ HSC cell manufacturing workflow
• Scaling up ex vivo cell therapy from discovery to preclinical using the NanoAssemblr™ LNP manufacturing platform

Reka Geczy

Associate Senior Scientist, Product Development at Cytiva

Reka is a Senior Scientist at Cytiva and is part of the team developing lipid nanoparticle reagents, such the T Cell Kit for mRNA and the recently launched CD34+ HSC LNP kits. Currently, her team is continuing the R&D of efficient lipid nanoparticle compositions for achieving the next generation of cell and gene therapies. Prior to her role at Cytiva, Reka got a PhD in Pharmaceutical Sciences from the University of British Columbia with high impact publications at the interface of microfluidics and drug delivery.

Watch now

SPEAKERS

Reka Geczy

Associate Senior Scientist, Product Development at Cytiva

You might also like

Case study: developing an ex vivo gene-modified hematopoietic stem cell treatment for a rare monogenic disease in a novel mouse model 

Rafael A. Badell-Grau

29 January 2025

in 35

Days

Register

Industry highlights: switching from manual to automated hematopoietic stem cell (HSC) gene engineering

A Marques Gomes, A Rubio Gomes, U Bissels et al.

6 November

Watch

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran

28 March

Watch

Optimized and scalable LNP composition for RNA vaccine delivery

Martin Rabel

25 September

Watch